Key result
Post-thrombolysis DAPT for minor stroke is linked to ~24% more good 90-day outcomes vs aspirin.
Why the study?
The study was conducted to verify the efficacy and safety of dual antiplatelet therapy after intravenous thrombolysis for acute minor ischemic stroke.
Does short-term dual antiplatelet therapy (aspirin + clopidogrel) improve clinical outcomes compared to aspirin alone in patients with acute minor ischemic stroke after intravenous thrombolysis?
Population
207 acute minor ischemic stroke patients who received rt-PA intravenous thrombolysis
Comparison
Aspirin plus clopidogrel vs aspirin alone
Design
Retrospective cohort study
Follow-up
90 days
Authors
Loading...
May support short-term DAPT post-thrombolysis in minor stroke; leaves open need for RCTs before practice change.
Cohort (n=207)
Does short-term dual antiplatelet therapy (aspirin + clopidogrel) improve clinical outcomes compared to aspirin alone in patients with acute minor ischemic stroke after intravenous thrombolysis?
Absolute Event Rate: 82.4% vs 66.7%
p-value: p=0.009
Short-term dual antiplatelet therapy after intravenous thrombolysis for acute minor ischemic stroke improves 90-day clinical outcomes without increasing bleeding risk.
Zhao et al. (2019) conducted a cohort in Acute minor ischemic stroke (AMIS) (n=207). Aspirin + clopidogrel (dual antiplatelet therapy) vs. Aspirin was evaluated on 90-day good clinical outcome (modified Rankin scale scores) (p=0.009). Dual antiplatelet therapy after intravenous thrombolysis for acute minor ischemic stroke improved 90-day good clinical outcomes compared to aspirin alone (82.4% vs 66.7%, p=0.009).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: